September 29, 2011 - Board Change
Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, today announces that Douglas Bates is stepping down from the board with effect from 28th September 2011. He will continue to serve the Company as a consultant. Mr Bates has served on the board since the Company's 2010 acquisition of Apredica, which Mr. Bates co-founded.
Mr Bates said: “It has been a privilege and an honour to take Apredica from conception to being successfully integrated with Cyprotex. Now that this is complete, I have decided to redirect my attention towards starting a new venture.”
The board thanks Mr. Bates for his continuing service and wishes him well in his new venture.
For further information:
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
Singer Capital Markets Limited (broker to Cyprotex)
Tel: +44 (0) 203 205 7500
Tel: +44 (0) 20 7831 3113